Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children Frederique RodieuxMelanie WilbauxMarc Pfister Review Article Open access 03 July 2015 Pages: 1183 - 1204
Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug–Drug Interactions Timothy EleyTushar GarimellaRichard J. Bertz Review Article 16 July 2015 Pages: 1205 - 1222
Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review Hazem ElewaEman El-MekatyKyle John Wilby Review Article 13 June 2015 Pages: 1223 - 1235
Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy Jessica K. RobertsChris StockmannCatherine M. T. Sherwin Original Research Article 20 May 2015 Pages: 1237 - 1244
A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child–Pugh Classification Julie SteelandtElodie Jean-BartMichel Tod Original Research Article 13 June 2015 Pages: 1245 - 1258
Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort Frederik VandenbergheMonia GuidiChin B. Eap Original Research Article 01 July 2015 Pages: 1259 - 1272
Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design Stéphanie LerouxMark A. TurnerOn behalf of the TINN (Treat Infections in NeoNates) and GRiP (Global Research in Paediatrics) Consortiums Original Research Article 11 June 2015 Pages: 1273 - 1285
Comment on Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design Joseph F. StandingBrian J. AndersonTuuli Metsvaht Letter to the Editor 07 November 2015 Pages: 1287 - 1288
Author’s Reply to Standing et al. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design Wei ZhaoEvelyne Jacqz-Aigrain Letter to the Editor 07 November 2015 Pages: 1289 - 1291
Comment on: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection” Nuggehally R. Srinivas Letter to the Editor 20 October 2015 Pages: 1293 - 1295
Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection” Florence Namour Commentary Open access 20 October 2015 Pages: 1297 - 1298
